These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22653876)

  • 1. Dosing regimen determination for juvenile idiopathic arthritis: a review of studies during drug development.
    Ji P; Chowdhury BA; Yim S; Sahajwalla CG
    J Pharm Sci; 2012 Aug; 101(8):2621-34. PubMed ID: 22653876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis.
    Correll CK; Bullock DR; Cafferty RM; Vehe RK
    Clin Rheumatol; 2018 Feb; 37(2):549-553. PubMed ID: 29103180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High doses of infliximab in the management of juvenile idiopathic arthritis.
    Tambralli A; Beukelman T; Weiser P; Atkinson TP; Cron RQ; Stoll ML
    J Rheumatol; 2013 Oct; 40(10):1749-55. PubMed ID: 23950184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel treatment options for juvenile idiopathic arthritis.
    Steigerwald KA; Ilowite NT
    Expert Rev Clin Pharmacol; 2015; 8(5):559-73. PubMed ID: 26294075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologics in juvenile idiopathic arthritis: a narrative review.
    Vanoni F; Minoia F; Malattia C
    Eur J Pediatr; 2017 Sep; 176(9):1147-1153. PubMed ID: 28725955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current therapy of polyarticular forms of juvenile idiopathic arthritis].
    Hospach A; Rühlmann JM; Weller-Heinemann F
    Z Rheumatol; 2016 Apr; 75(3):284-91. PubMed ID: 27001055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Guidelines on biologic drugs for the treatment of children with juvenile idiopathic arthritis (JIA)].
    Bukovac LT; Vidović M; Lamot L; Perica M; Harjacek M;
    Reumatizam; 2013; 60(1):57-66. PubMed ID: 24003687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.
    Guzman J; Oen K; Tucker LB; Huber AM; Shiff N; Boire G; Scuccimarri R; Berard R; Tse SM; Morishita K; Stringer E; Johnson N; Levy DM; Duffy KW; Cabral DA; Rosenberg AM; Larché M; Dancey P; Petty RE; Laxer RM; Silverman E; Miettunen P; Chetaille AL; Haddad E; Houghton K; Spiegel L; Turvey SE; Schmeling H; Lang B; Ellsworth J; Ramsey S; Bruns A; Campillo S; Benseler S; Chédeville G; Schneider R; Yeung R; Duffy CM;
    Ann Rheum Dis; 2015 Oct; 74(10):1854-60. PubMed ID: 24842571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Juvenile idiopathic arthritis--current and future therapies.
    Kahn P
    Bull NYU Hosp Jt Dis; 2009; 67(3):291-302. PubMed ID: 19852753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model-Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis.
    Gandhi Y; Passarell JA; Roy A; Murthy B
    J Clin Pharmacol; 2021 May; 61(5):688-699. PubMed ID: 33284480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease activity of idiopathic juvenile arthritis continues through adolescence despite the use of biologic therapies.
    Vidqvist KL; Malin M; Varjolahti-Lehtinen T; Korpela MM
    Rheumatology (Oxford); 2013 Nov; 52(11):1999-2003. PubMed ID: 23893666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [BIOLOGIC THERAPY FOR JUVENILE IDIOPATHIC ARTHRITIS].
    Brik R
    Harefuah; 2017 Oct; 156(10):659-662. PubMed ID: 29072387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives.
    Wahezi DM; Ilowite NT
    Expert Opin Pharmacother; 2013 Jun; 14(8):975-89. PubMed ID: 23528005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.
    Pagnini I; Bertini F; Cimaz R
    Paediatr Drugs; 2016 Apr; 18(2):101-8. PubMed ID: 26939782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population pharmacokinetic model using allometric scaling for baricitinib in patients with juvenile idiopathic arthritis.
    Decker RL; Steven Ernest C; Radtke DB; Wang R; Araújo J; Keller SY; Zhang X
    CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):970-981. PubMed ID: 38532270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Juvenile idiopathic arthritis - what the clinician needs to know.
    Kahn PJ
    Bull Hosp Jt Dis (2013); 2013; 71(3):194-9. PubMed ID: 24151944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Access to pediatric rheumatology care for Juvenile Idiopathic Arthritis in the United Arab Emirates.
    Khawaja K; Al-Maini M
    Pediatr Rheumatol Online J; 2017 May; 15(1):41. PubMed ID: 28511684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigational drugs for treatment of juvenile idiopathic arthritis.
    Mauro A; Rigante D; Cimaz R
    Expert Opin Investig Drugs; 2017 Apr; 26(4):381-387. PubMed ID: 28277884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients.
    Romano M; Pontikaki I; Gattinara M; Ardoino I; Donati C; Boracchi P; Meroni PL; Gerloni V
    Reumatismo; 2014 Mar; 65(6):278-85. PubMed ID: 24705031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.